Immunology | Preclinical Developments | UNITED STATES

CytoAgents

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

Lead Product(s): GP1681

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $1.6 million Upfront Cash: Undisclosed

Deal Type: Funding May 13, 2020

Details:

The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.

Singota Solutions

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

Singota Solutions Collaborates with Noveome Biotherapeutics

Lead Product(s): ST266

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Noveome Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 12, 2020

Details:

Under the terms of the collaboration, Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials.

Noveome Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

Noveome Biotherapeutics Receives $4 Million Grant From Commonwealth of Pennsylvania

Lead Product(s): ST266

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania

Deal Size: $4.0 million Upfront Cash: Undisclosed

Deal Type: Funding May 07, 2020

Details:

Funding enables existing clinical trial of its lead product candidate, ST266, to proceed as company joins global response with covid-19 program.

ProThera Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

ProThera Biologics and Takeda Enter Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins

Lead Product(s): Plasma-derived Inter-alpha Inhibitor Proteins therapy

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 23, 2020

Details:

As part of the agreement, ProThera and Takeda will work together on IND-enabling activities, with development led by Takeda's dedicated Plasma Derived Therapies R&D organization.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study

Lead Product(s): Anandamide

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

The study conducted in partnership with Zylö Therapeutics confirmed mice treated with Anandamide (AEA)-loaded particles experienced lesions that regressed in size and severity.

twoXAR Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel Lupus Drug Leads

Lead Product(s): TXR-711

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 21, 2020

Details:

TXR-711 and TXR-712, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Immutep

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

Immutep Advances Cell Line Development for IMP761

Lead Product(s): IMP761

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 15, 2020

Details:

Using its STEP®-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761.

Incyte Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

FCE Pharma

Participation Not Confirmed

Update your events

Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm

Lead Product(s): Ruxolitinib

Therapeutic Area: Immunology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 02, 2020

Details:

Novartis plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction called cytokine storm in COVID-19.